CRISPR technology has enabled rapid advances in gene editing, but it also can trigger unintended consequences
CRISPR technology has enabled rapid advances in gene editing. CRISPR-based therapies will soon be in the clinic (along with other methods, like base editing). As we prepare to move from the laboratory bench to the patient’s bedside we need to be mindful of unintended consequences, and how to proactively look for and address these concerns through pre-clinical testing.
In this podcast episode, narrator Chris Dowdy PhD, Client and Scientific Portfolio Manager, is joined by Julia Schueler PhD, Research Director at Charles River’s Freiburg site to discuss how in silico testing, in vitro prediction using cell-free DNA or cell-based genome-wide assays can be used to mitigate the off-target effects of CRISPR.
As Dowdy and Schueler point out, resolving these problems in the preclinical setting will go a long way toward making CRISPR a viable tool in human studies.